Eli Lilly and Company Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | $2.46 | $2.47 | $2.47 |
| Q2 2024 | 4 | $2.74 | $2.74 | $2.74 |
| Q3 2024 | 5 | $1.36 | $1.48 | $1.42 |
| Q4 2024 | 12 | $5.33 | $5.58 | $5.47 |
| Q1 2025 | 1 | $5.00 | $5.23 | $5.15 |
| Q2 2025 | 1 | $5.45 | $5.70 | $5.62 |
| Q3 2025 | 1 | $5.77 | $6.04 | $5.95 |
| Q4 2025 | 1 | $4.32 | $4.52 | $4.45 |
Eli Lilly and Company Earnings Date And Information
Eli Lilly and Company last posted its earnings results on Wednesday, October 30th, 2024. The company reported $1.18 earnings per share for the quarter, missing analysts' consensus estimates of $1.47 by $0.29. The company had revenue of 11.44 B for the quarter and had revenue of 34.12 B for the year. Eli Lilly and Company has generated $6 earnings per share over the last year ($5.8 diluted earnings per share) and currently has a price-to-earnings ratio of 84.64. Eli Lilly and Company has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 3rd, 2025 based on prior year's report dates.
Eli Lilly and Company Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/30/2024 | Q3 2024 | $1.47 | $1.08 | -0.39 | $12.10 B | $11.44 B |
| 08/08/2024 | Q2 2024 | $2.60 | $3.29 | 0.69 | $9.98 B | $11.30 B |
| 04/30/2024 | Q1 2024 | $2.46 | $2.49 | 0.03 | $8.77 B | |
| 02/21/2024 | Q4 2023 | $2.31 | $9.35 B | |||
| 11/02/2023 | Q3 2023 | -$0.08 | -$0.06 | 0.02 | $8.97 B | $9.50 B |
| 08/08/2023 | Q2 2023 | $1.98 | $1.96 | -0.02 | $7.58 B | $8.31 B |
| 04/27/2023 | Q1 2023 | $1.73 | $1.49 | -0.24 | $6.96 B | |
| 02/22/2023 | Q4 2022 | $2.04 | $7.30 B | |||
| 11/01/2022 | Q3 2022 | $1.92 | $1.61 | -0.31 | $6.89 B | $6.94 B |
| 08/04/2022 | Q2 2022 | $1.69 | $1.06 | -0.63 | $6.85 B | $6.49 B |
| 04/29/2022 | Q1 2022 | $2.11 | $7.81 B | |||
| 02/23/2022 | Q4 2021 | $1.81 | $8.00 B | |||
| 10/27/2021 | Q3 2021 | $1.22 | $6.64 B | $6.77 B | ||
| 08/03/2021 | Q2 2021 | $1.89 | $1.53 | -0.36 | $6.60 B | $6.74 B |
| 04/30/2021 | Q1 2021 | $1.49 | $6.81 B | |||
| 02/17/2021 | Q4 2020 | $2.21 | $7.44 B | |||
| 10/28/2020 | Q3 2020 | $1.33 | $5.88 B | $5.74 B | ||
| 07/31/2020 | Q2 2020 | $1.56 | $5.76 B | $5.50 B | ||
| 05/01/2020 | Q1 2020 | $1.60 | $5.86 B | |||
| 02/19/2020 | Q4 2019 | $1.56 | $6.11 B |
Eli Lilly and Company Earnings: Frequently Asked Questions
-
When is Eli Lilly and Company's earnings date?
Eli Lilly and Company has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 3rd, 2025 based off last year's report dates.
-
How can I listen to Eli Lilly and Company's earnings conference call?
The conference call for Eli Lilly and Company's latest earnings report can be listened to online.
-
How can I read Eli Lilly and Company's conference call transcript?
The conference call transcript for Eli Lilly and Company's latest earnings report can be read online.
-
How much revenue does Eli Lilly and Company generate each year?
Eli Lilly and Company (:LLY) has a recorded annual revenue of $34.12 B.
-
How much profit does Eli Lilly and Company generate each year?
Eli Lilly and Company (:LLY) has a recorded net income of $34.12 B. Eli Lilly and Company has generated $5.8 earnings per share over the last four quarters.
-
What is Eli Lilly and Company's price-to-earnings ratio?
Eli Lilly and Company (:LLY) has a price-to-earnings ratio of 84.64 and price/earnings-to-growth ratio is 5.96.
